Center for Digestive and Liver Diseases, Inc.  © 2013  |  Privacy policy

like us

Protocol M14-033

 

A FDA approved drug for Ulcerative Colitis (Humira) study evaluating higher induction vs convertional dosing to see if better outcomes and is safe.

 

A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

 

 

 

I am interested in more information about this study.

 
SEND CLEAR